CDH5 and cancer: Muscle samples of participants with cancer also demonstrated significantly reduced VE-cadherin when compared to those of controls (Fig. 6i,j) and this decrease was accompanied by a decrease in overall muscle vascular density as assessed by staining for the endothelial marker CD31 (Extended Data Fig. 8f–h).